Extended Data Fig. 1: Nasal anti-CD3 improves behavioral outcomes at different treatment regimens and TBI severities. | Nature Neuroscience

Extended Data Fig. 1: Nasal anti-CD3 improves behavioral outcomes at different treatment regimens and TBI severities.

From: Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent Treg–microglia crosstalk

Extended Data Fig. 1

(a) Behavioral testing in the early treatment regimen for males of rotarod, Morris water maze, probe trial, and anxiety like behavior that is measured by the open field was assessed between (Sham-Iso n = 8, TBI-Iso n = 12, and TBI-aCD3 n = 12) groups in the early and (b) delayed treatment regimen for males and (c) immediate for females. Morris water maze analyzed by two-factor repeated measures two-way ANOVA (group x time); others by one-way ANOVA with Tukey’s multiple comparisons. Data shown as mean ± SEM. (d) Behavioral testing in the immediate treatment regimen for males in severe TBI (Depth: 1.5 mm, Diameter: 3.0 mm of the impact tip) of rotarod, Morris water maze, probe trial, and anxiety like behavior that is measured by the open field was assessed between (Sham-Iso n = 8, TBI-Iso n = 12, and TBI-aCD3 n = 12) groups in males and (e) females. Morris water maze analyzed by two-factor repeated measures two-way ANOVA (group x time); others by one-way ANOVA with Tukey’s multiple comparisons. Data shown as mean ± SEM. All data are biological replicates and are representative from two independent experiments. n.s. = non-significant.

Back to article page